The patients in this study will have scars that are less than two years old, with the therapy expected to have a greater impact on more recent scarring. In the previous study, the average age of the scars treated in the 42 patients was 13 years!
One of the learnings from the previous study, not surprisingly, is that more established scars are more difficult to treat.
The new formulation will also provided new (extended) IP around the asset. Phillips said the company only files patents around specific compounds when they move into Phase I studies.
Phillips said the data from the previous study with SNT-6302 has de-risked the asset and allows Synatra to move ahead more quickly and decisively with the new formulation. He does not expect to be surprised from the forthcoming result having data from the previous trial.
If the trial goes as planned, Syntara will then move into a larger Phase II study.
Trials with SNT-6203 to Continue
Professor Wood's team in Perth will continue with the original for- mulation of the therapy (SNT-6203), investigating the longer-term impact on the more difficult-to-treat keloid scars.
Hypertropic scars get better with time, said Professor Wood, but keloid scars will not and will expand. There is also a greater volume of skin affected in keloid scars.
Summary
Syntara finished last year with a proforma cash balance in ex- cess of $20 million. Other milestones to come, other than results from the two new scar studies, includes more mature data from its myelofibrosis study, and results from its Parkinsons study early next year.
Biosharesrecommendation:Speculative Buy Class ATop Line Phase II data for SNT 5505 is now under 30 days away
SNT 7.2 cents Share Price??? MC $116m????
Topline Phase II data is one of the key Catalysts for a Biotech and delivers a substantial Inflection Point .... really SNT right about now should be breaking the last 52 week high as we drill down towards confirmation and completion of circa 5 Years of Trialing... maximising SH Value now comes down to direct company action...
Best of Luck to all invested NZT
